GSK already has a foothold in HIV/infectious disease and respiratory but wants to grow its oncology and immune-inflammation units. The cancer focus is somewhat of a turnaround for GSK, which in 2014 under Witty traded away most of its oncology assets in exchange for the Novartis vaccines stable in a multibillion-dollar deal.
He adds that while Sin has experience in oncology, with analysts on the call asking if he will be a part of the company’s drive to build out a bigger cancer pipeline, he too has experience in technology, something GSK has embraced in the past,